Study guide

3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments

PEBC Pharmacist Qualifying Examination Part I MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation

1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice

2 Chapter 2: Ethics, Scope of Practice & Safety Culture

2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement

3 Chapter 3: Pharmaceutical Calculations & Posology

3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)

4 Chapter 4: Compounding, Dispensing & Product Integrity

4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control

5 Chapter 5: Clinical Pharmacology & Pharmacokinetics

5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities

6 Chapter 6: Evidence-Based Medicine & Literature Appraisal

6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics

7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD

7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)

8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation

8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)

9 Chapter 9: Endocrine & Metabolic Disorders

9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)

10 Chapter 10: Respiratory & Gastrointestinal Disorders

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis

11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship

11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections

12 Chapter 12: Central Nervous System & Mental Health

12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome

13 Chapter 13: Special Populations, Pain Management & Substance Use

13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy

14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care

14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care

15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health

15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder

16 Chapter 16: Immunization & Health Promotion

16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health

17 Chapter 17: Patient Care Process, Communication & Stewardship

17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship

3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments

Key Takeaways Explain This Topic AI

Pediatric weight-based dosing (mg/kg/day or mg/kg/dose) must always be cross-checked against adult maximum single and daily limits; for example, high-dose amoxicillin at 90 mg/kg/day divided BID for acute otitis media must not exceed the adult standard limit of 4,000 mg/day.

Body surface area (BSA) calculated via the Mosteller formula ( BSA (m 2 ) = height (cm) × weight (kg) 3600 \text{BSA (m}^2\text{)} = \sqrt{\frac{\text{height (cm)} \times \text{weight (kg)}}{3600}} BSA (m 2 ) = 3600 height (cm) × weight (kg) ​ ​ ) provides the dosing index for narrow-therapeutic-index oncology regimens, where doses are often capped at 2.0 m 2 2.0\text{ m}^2 2.0 m 2 to prevent overexposure in obese patients.

Ophthalmic days supply calculations use standard droplet calibration (20 drops/mL for solutions, 15 drops/mL for viscous gels/suspensions) and must strictly apply the 28-day beyond-use date (BUD) limit for opened multi-dose preserved containers regardless of remaining physical volume.

Insulin days supply calculations must account for the safety priming shot before each injection (usually 2 units) and adhere to product-specific in-use room-temperature stability limits (28 days for most rapid-acting and glargine U-100 products, 42 days for detemir, 56 days for degludec and glargine U-300; human insulins vary by product).

Metered-dose inhaler (MDI) days supply equals total labelled canister actuations divided by prescribed daily puffs, incorporating mandatory initial test sprays and dose-counter tracking to prevent patients using empty propellant-only canisters.

Last updated: October 2026

3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments

Posology—the science of dosage regimens—requires clinicians to calculate patient-specific doses and verify day-supply limits across specialized delivery systems. In pediatric, geriatric, and oncology medicine, fixed adult dosing fails because organ clearance, metabolic capacity, and volume of distribution change dramatically across body size and life stages. Pharmacists must navigate weight-based dosing, body surface area (BSA) determinations, and stringent supply limits for ophthalmics, insulin devices, and respiratory inhalers.

Pediatric and Weight-Based Posology Principles

Pediatric doses are conventionally prescribed according to body mass, expressed either as milligrams per kilogram per day ( mg/kg/day \text{mg/kg/day} mg/kg/day ) or milligrams per kilogram per single dose ( mg/kg/dose \text{mg/kg/dose} mg/kg/dose ):

Daily Divided Posology ( mg/kg/day \text{mg/kg/day} mg/kg/day ) : The total calculated milligram quantity must be divided into equal fractional doses matching the dosing frequency (e.g., BID = divided into 2 doses every 12 hours; TID = divided into 3 doses every 8 hours).

Per-Dose Posology ( mg/kg/dose \text{mg/kg/dose} mg/kg/dose ) : The calculated milligram quantity is administered at each individual dosing event without mathematical division.

Clinical Benchmark: Canadian Paediatric Society Guidelines for Acute Otitis Media

In Canadian pediatric practice, the Canadian Paediatric Society (CPS) recommends high-dose amoxicillin as first-line therapy when a child with acute otitis media (AOM) needs an antibiotic, because it covers penicillin-intermediate Streptococcus pneumoniae :

Recommended Dosage : 75 – 90 mg/kg/day 75\text{--}90\text{ mg/kg/day} 75 – 90 mg/kg/day divided into two doses every 12 hours (BID); three-times-daily dosing is an alternative.

Duration : 10 days for children younger than 2 years and for those with a perforated tympanic membrane or recurrent AOM; 5 days for children 2 years and older with uncomplicated AOM.

Pharmacodynamic Target : The high-dose strategy achieves middle ear fluid concentrations exceeding the minimum inhibitory concentration (MIC) of intermediate-resistant pneumococci for greater than 40 % 40\% 40% to 50 % 50\% 50% of the 12-hour dosing interval ( T > MIC T > \text{MIC} T > MIC ).

The Mandatory Adult Maximum Cap Rule

Important

A weight-based pediatric calculation must never exceed the standard adult maximum single dose or adult maximum daily dose unless explicitly indicated in specialized high-dose protocol guidelines. For high-dose amoxicillin, Canadian references commonly cap the total at about 4 , 000 mg/day 4,000\text{ mg/day} 4 , 000 mg/day . If an adolescent weighing 60 kg 60\text{ kg} 60 kg is prescribed 90 mg/kg/day 90\text{ mg/kg/day} 90 mg/kg/day ( 5 , 400 mg/day 5,400\text{ mg/day} 5 , 400 mg/day ), the pharmacist should contact the prescriber and cap the regimen at about 4 , 000 mg/day 4,000\text{ mg/day} 4 , 000 mg/day (for example, 2 , 000 mg 2,000\text{ mg} 2 , 000 mg BID).

Step-by-Step Worked Pediatric Calculation

Clinical Case : A 3-year-old child weighing 15 kg 15\text{ kg} 15 kg has AOM with ear discharge from a perforated tympanic membrane, so the 10-day CPS course applies. The child is prescribed amoxicillin suspension at 90 mg/kg/day 90\text{ mg/kg/day} 90 mg/kg/day divided BID for 10 days. The pharmacy stocks amoxicillin 400 mg / 5 mL 400\text{ mg}/5\text{ mL} 400 mg /5 mL ( 80 mg/mL 80\text{ mg/mL} 80 mg/mL ) in 100 mL 100\text{ mL} 100 mL bottles.

Calculate Total Daily Dose : Daily Dose = 15 kg × 90 mg/kg/day = 1 , 350 mg/day \text{Daily Dose} = 15\text{ kg} \times 90\text{ mg/kg/day} = 1,350\text{ mg/day} Daily Dose = 15 kg × 90 mg/kg/day = 1 , 350 mg/day

Calculate Dose per Administration (BID) : Single Dose = 1 , 350 mg/day 2 doses/day = 675 mg BID \text{Single Dose} = \frac{1,350\text{ mg/day}}{2\text{ doses/day}} = 675\text{ mg BID} Single Dose = 2 doses/day 1 , 350 mg/day ​ = 675 mg BID (Check cap: 1 , 350 mg/day < 4 , 000 mg/day 1,350\text{ mg/day} < 4,000\text{ mg/day} 1 , 350 mg/day < 4 , 000 mg/day ceiling. Verified safe).

Calculate Volume per Dose : Volume per Dose = 675 mg 80 mg/mL = 8.4375 mL ≈ 8.4 mL BID \text{Volume per Dose} = \frac{675\text{ mg}}{80\text{ mg/mL}} = 8.4375\text{ mL} \approx 8.4\text{ mL BID} Volume per Dose = 80 mg/mL 675 mg ​ = 8.4375 mL ≈ 8.4 mL BID

Calculate Total Regimen Volume & Dispense Package : Total Volume = 8.4375 mL/dose × 2 doses/day × 10 days = 168.75 mL \text{Total Volume} = 8.4375\text{ mL/dose} \times 2\text{ doses/day} \times 10\text{ days} = 168.75\text{ mL} Total Volume = 8.4375 mL/dose × 2 doses/day × 10 days = 168.75 mL Because amoxicillin is supplied in 100 mL 100\text{ mL} 100 mL bottles, dispensing a single 100 mL 100\text{ mL} 100 mL bottle would provide only 5.9 days of therapy. The pharmacist must dispense two 100 mL 100\text{ mL} 100 mL bottles ( 200 mL 200\text{ mL} 200 mL total) with a calibrated oral syringe, counselling the parent to discard the remainder after 14 days.

Body Surface Area (BSA) and Narrow-Therapeutic-Index Regimens

Body surface area (BSA) correlates more strongly with glomerular filtration rate, cardiac output, and hepatic metabolic capacity than total body weight. Consequently, BSA ( m 2 m^2 m 2 ) is the clinical standard for antineoplastic agents (cytotoxic chemotherapy), monoclonal antibodies, and pediatric burn/intensive care regimens.

The Mosteller Formula

The Mosteller formula is the most widely used BSA method in clinical practice because it is simple and agrees closely with the DuBois and DuBois reference formula. The PEBC formula sheet does not list a BSA formula, so an exam item that needs BSA gives either the formula or the BSA value in the stem:

BSA (m 2 ) = Height (cm) × Weight (kg) 3600 \text{BSA (m}^2\text{)} = \sqrt{\frac{\text{Height (cm)} \times \text{Weight (kg)}}{3600}} BSA (m 2 ) = 3600 Height (cm) × Weight (kg) ​ ​

When height is measured in inches and weight in pounds:

BSA (m 2 ) = Height (inches) × Weight (lbs) 3131 \text{BSA (m}^2\text{)} = \sqrt{\frac{\text{Height (inches)} \times \text{Weight (lbs)}}{3131}} BSA (m 2 ) = 3131 Height (inches) × Weight (lbs) ​ ​

Parameter Mosteller Formula DuBois and DuBois Formula

Mathematical Expression BSA = Height (cm) × Weight (kg) 3600 \text{BSA} = \sqrt{\frac{\text{Height (cm)} \times \text{Weight (kg)}}{3600}} BSA = 3600 Height (cm) × Weight (kg) ​ ​ BSA = 0.007184 × Height 0.725 × Weight 0.425 \text{BSA} = 0.007184 \times \text{Height}^{0.725} \times \text{Weight}^{0.425} BSA = 0.007184 × Height 0.725 × Weight 0.425

Calculation Complexity Simple square root of arithmetic product Requires exponential logarithmic calculators

Clinical Concordance Within 1 % – 2 % 1\%\text{--}2\% 1% – 2% of DuBois across all adult weight tiers Reference standard for physiological research

  • Exam Expectation Apply it when the stem supplies the formula or values Rarely used in exam items
  • Step-by-Step Worked BSA Calculation

Clinical Case : An adult patient with lung carcinoma is 168 cm 168\text{ cm} 168 cm tall and weighs 65 kg 65\text{ kg} 65 kg . The oncologist prescribes cisplatin at 75 mg/m 2 75\text{ mg/m}^2 75 mg/m 2 IV every 21 days.

Calculate BSA via Mosteller : Product = 168 × 65 = 10 , 920 \text{Product} = 168 \times 65 = 10,920 Product = 168 × 65 = 10 , 920 Quotient = 10 , 920 3600 = 3.0333 \text{Quotient} = \frac{10,920}{3600} = 3.0333 Quotient = 3600 10 , 920 ​ = 3.0333 BSA = 3.0333 ≈ 1.7416 m 2 ≈ 1.74 m 2 \text{BSA} = \sqrt{3.0333} \approx 1.7416\text{ m}^2 \approx 1.74\text{ m}^2 BSA = 3.0333 ​ ≈ 1.7416 m 2 ≈ 1.74 m 2

Calculate Prescribed Chemotherapy Dose : Dose = 1.7416 m 2 × 75 mg/m 2 = 130.62 mg ≈ 131 mg \text{Dose} = 1.7416\text{ m}^2 \times 75\text{ mg/m}^2 = 130.62\text{ mg} \approx 131\text{ mg} Dose = 1.7416 m 2 × 75 mg/m 2 = 130.62 mg ≈ 131 mg

Note

In oncology practice, to prevent lethal overdoses in severely obese patients, clinical protocols frequently apply an empiric BSA cap (typically at 2.0 m 2 2.0\text{ m}^2 2.0 m 2 or 2.2 m 2 2.2\text{ m}^2 2.2 m 2 ) unless the patient is being treated with curative intent under close therapeutic drug monitoring.

Precision Days Supply Calculations for Specialized Delivery Systems

Determining the exact days supply of a prescription is an essential dispensing competency. Underestimating days supply leads to premature refills and public drug plan audit clawbacks (e.g., Ontario Drug Benefit, Fair PharmaCare in British Columbia), while overestimating days supply can leave patients without medication.

Ophthalmic Preparations

Ophthalmic dropper tips are manufactured to deliver standardized droplet volumes, but physical surface tension varies with drug viscosity:

Standard Exam Calibration : 1 mL = 20 drops 1\text{ mL} = 20\text{ drops} 1 mL = 20 drops for aqueous solutions ( 0.05 mL 0.05\text{ mL} 0.05 mL per drop).

Viscous Suspensions & Emulsions : 1 mL = 15 drops 1\text{ mL} = 15\text{ drops} 1 mL = 15 drops (e.g., cyclosporine ophthalmic emulsions, gellified drops).

Total Droplets = Bottle Volume (mL) × Drop Factor (drops/mL) \text{Total Droplets} = \text{Bottle Volume (mL)} \times \text{Drop Factor (drops/mL)} Total Droplets = Bottle Volume (mL) × Drop Factor (drops/mL) Mathematical Days Supply = Total Droplets Drops Required per Day \text{Mathematical Days Supply} = \frac{\text{Total Droplets}}{\text{Drops Required per Day}} Mathematical Days Supply = Drops Required per Day Total Droplets ​

Caution

The In-Use Discard Date for Eye Drops : Once a multi-dose preserved ophthalmic container is opened, it is exposed to contamination. Many Canadian hospital and long-term care policies discard multi-dose eye drops 28 days after opening . The product monograph can set a different in-use period; latanoprost, for example, may be kept at room temperature for up to 6 weeks after opening. The days supply is therefore the lesser of the mathematical volume exhaustion or the applicable discard period .

Ophthalmic Example : A preserved glaucoma solution labelled "discard 28 days after opening" is supplied in a 10 mL 10\text{ mL} 10 mL bottle. The prescription reads: Instill 1 drop into both eyes (OU) twice daily.

Total drops: 10 mL × 20 drops/mL = 200 drops 10\text{ mL} \times 20\text{ drops/mL} = 200\text{ drops} 10 mL × 20 drops/mL = 200 drops .

Daily usage: 1 drop × 2 eyes × 2 times = 4 drops/day.

Mathematical exhaustion: 50 days 50\text{ days} 50 days .

In-use discard limit: 28 days 28\text{ days} 28 days .

Clinical Days Supply : 28 days 28\text{ days} 28 days (the remaining drops are discarded on day 28).

By contrast, latanoprost 0.005 % 0.005\% 0.005% in a 2.5 mL 2.5\text{ mL} 2.5 mL bottle at 1 drop OD daily gives 50 50 50 drops = 50 50 50 days, capped by its 6-week (42-day) in-use limit.

Insulin Pens and Vials

Most commercial insulin formulations are supplied at standard U-100 concentration ( 100 units/mL 100\text{ units/mL} 100 units/mL ):

Prefilled Pen Cartridges : 3 mL = 300 units 3\text{ mL} = 300\text{ units} 3 mL = 300 units .

Multi-Dose Vials : 10 mL = 1 , 000 units 10\text{ mL} = 1,000\text{ units} 10 mL = 1 , 000 units .

Mandatory Safety Priming ("Air Shot")

Most pen instructions for use tell patients to dial and expel a 2 unit 2\text{ unit} 2 unit safety test before every injection (Toujeo SoloStar uses 3 units). This clears air from the needle assembly and confirms needle patency. Dosing calculations must account for this priming waste:

Daily Insulin Usage = Prescribed Units/Day + ( Number of Injections/Day × 2 units ) \text{Daily Insulin Usage} = \text{Prescribed Units/Day} + (\text{Number of Injections/Day} \times 2\text{ units}) Daily Insulin Usage = Prescribed Units/Day + ( Number of Injections/Day × 2 units )

In-Use Room-Temperature Stability Limits

Once an insulin pen or vial is removed from refrigeration and placed into active room-temperature use ( 15 ∘ C 15^\circ\text{C} 1 5 ∘ C to 30 ∘ C 30^\circ\text{C} 3 0 ∘ C ), it degrades over time:

  • Insulin Product Brand Examples In-Use Room-Temperature Limit
  • Most Rapid-Acting & Glargine U-100 Insulins Humalog, NovoRapid, Apidra, Lantus, Basaglar 28 Days

Human Insulins (Regular, NPH) Humulin, Novolin ge Product-specific (for example, Humulin N pens 14 days, Humulin vials 31 days); check the monograph

  • Insulin Detemir Levemir FlexTouch 42 Days
  • Insulin Degludec & Concentrated Glargine Tresiba (U-100, U-200), Toujeo SoloStar (U-300) 56 Days

The days supply for an individual insulin pen is: min ⁡ ( ⌊ Total Cartridge Units Daily Insulin Usage ⌋ , In-Use Stability Days ) \min\left(\lfloor\frac{\text{Total Cartridge Units}}{\text{Daily Insulin Usage}}\rfloor, \text{In-Use Stability Days}\right) min ( ⌊ Daily Insulin Usage Total Cartridge Units ​ ⌋ , In-Use Stability Days ) .

Metered-Dose Inhalers (MDIs) and Dry Powder Inhalers (DPIs)

Inhaler days supply is governed by total labelled actuations divided by daily inhalation frequency:

Salbutamol HFA (Ventolin) : 200 actuations 200\text{ actuations} 200 actuations per canister. If prescribed 2 puffs QID scheduled: 200 8 puffs/day = 25 days supply \frac{200}{8\text{ puffs/day}} = 25\text{ days supply} 8 puffs/day 200 ​ = 25 days supply .

Fluticasone propionate (Flovent HFA) : 120 actuations 120\text{ actuations} 120 actuations . If prescribed 2 puffs BID: 120 4 puffs/day = 30 days supply \frac{120}{4\text{ puffs/day}} = 30\text{ days supply} 4 puffs/day 120 ​ = 30 days supply .

Priming Discard : When initializing a new canister or when an MDI has not been used for > 7 – 14 days >7\text{--}14\text{ days} > 7 – 14 days , 2 to 4 priming sprays must be sprayed into the air and deducted from available actuations.

  • Pharmacokinetic Considerations in Pediatric and Geriatric Dosing
  • Pediatric Age-Related Physiology

Total Body Water : Neonates consist of 75 % – 80 % 75\%\text{--}80\% 75% – 80% total body water (compared to 55 % – 60 % 55\%\text{--}60\% 55% – 60% in adults). Hydrophilic medications (e.g., aminoglycosides, beta-lactams) require higher initial mg/kg \text{mg/kg} mg/kg loading doses to achieve therapeutic peak concentrations.

Hepatic Glucuronidation : Phase II conjugation enzymes are severely immature in infants < 2 months <2\text{ months} < 2 months , leading to toxic accumulation of chloramphenicol (Gray Baby Syndrome) or bilirubin displacement.

Glomerular Filtration Rate : At birth, GFR is approximately 20 – 40 mL/min/1.73 m 2 20\text{--}40\text{ mL/min/1.73 m}^2 20 – 40 mL/min/1.73 m 2 , maturing to adult levels around 1 year of age.

Geriatric Age-Related Physiology

Renal Function Decline : Nephron mass and glomerular filtration decrease by roughly 1 mL/min 1\text{ mL/min} 1 mL/min per year after age 40. Normal serum creatinine values in elderly patients often conceal severe renal impairment due to age-related sarcopenia (reduced muscle mass).

Altered Body Composition : Increased percentage of body adipose tissue and decreased total body water increase the volume of distribution ( V d V_d V d ​ ) and elimination half-life of lipophilic drugs (e.g., diazepam, flurazepam), increasing delirium and fall risks.

Deprescribing & Beers Criteria : Geriatric posology mandates "starting low and going slow," actively tapering inappropriate anticholinergic, sedative-hypnotic, and NSAID therapies.